Olfactory threshold predicts treatment response in relapsing multiple sclerosis

被引:3
|
作者
Bsteh, Gabriel [1 ]
Hegen, Harald [2 ]
Berek, Klaus [2 ]
Altmann, Patrick [1 ]
Auer, Michael [2 ]
Di Pauli, Franziska [2 ]
Haider, Lukas [3 ]
Leutmezer, Fritz [1 ]
Rommer, Paulus [1 ]
Walchhofer, Lisa-Maria [4 ]
Wurth, Sebastian [5 ]
Zinganell, Anne [2 ]
Deisenhammer, Florian [2 ]
Berger, Thomas [1 ]
机构
[1] Med Univ Vienna, Dept Neurol, Waehringer Guertel 18-20, A-1090 Vienna, Austria
[2] Med Univ Innsbruck, Dept Neurol, Innsbruck, Austria
[3] Med Univ Vienna, Dept Neuroradiol, Vienna, Austria
[4] Med Univ Innsbruck, Dept Neuroradiol, Innsbruck, Austria
[5] Med Univ Graz, Dept Neurol, Graz, Austria
关键词
Multiple sclerosis; olfactory threshold; disease-modifying treatment; relapse; MRI; treatment response; INTERFERON-BETA; DYSFUNCTION; SMELL; MRI;
D O I
10.1177/13524585221079744
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Olfactory threshold (OT) is associated with short-term inflammatory activity in relapsing multiple sclerosis (RMS). Objective: We aimed to investigate OT for prediction of treatment response in RMS. Methods: In this 5-year prospective study on 123 RMS patients, OT was measured at disease-modifying treatment (DMT) initiation (M0), after 3 months (M3), and 12 months (M12) by Sniffin' Sticks test. Primary endpoint was defined as an absence of relapse during the observation period, with Expanded Disability Status Scale (EDSS) progression and magnetic resonance imaging (MRI) activity being the secondary endpoints. Optimal cutoff values were determined by receiver operating characteristic analyses and their predictive value assessed by multivariable Cox regression models. Results: Higher OT scores at M0, M3, and M12 were independently associated with decreased relapse probability with the strongest risk reduction at M3 (hazard ratio (HR) = 0.44, p < 0.001). Improvement of OT scores from M0 to M3 (Delta OTM3) was also associated with reduced relapse risk (HR = 0.12, p < 0.001). OT score > 6.5 at M3 was the strongest predictor of relapse freedom (HR = 0.10, p < 0.001) with high diagnostic accuracy (positive predictive value (PPV) = 87%), closely followed by Delta OTM3 > 0.5 (HR = 0.12, p < 0.001, PPV = 86%). Conclusions: OT is an independent predictor of freedom of disease activity upon DMT initiation within 5 years and may be a useful biomarker of treatment response.
引用
收藏
页码:1541 / 1552
页数:12
相关论文
共 50 条
  • [31] Ozanimod for the treatment of relapsing remitting multiple sclerosis
    Rasche, Ludwig
    Paul, Friedemann
    EXPERT OPINION ON PHARMACOTHERAPY, 2018, 19 (18) : 2073 - 2086
  • [32] Laquinimod in the treatment of relapsing remitting multiple sclerosis
    Hainke, Undine
    Thomas, Katja
    Ziemssen, Tjalf
    EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY, 2016, 12 (06) : 701 - 709
  • [33] Transient impairment of olfactory threshold in acute multiple sclerosis relapse
    Bsteh, Gabriel
    Hegen, Harald
    Ladstaetter, Felix
    Berek, Klaus
    Amprosi, Matthias
    Wurth, Sebastian
    Auer, Michael
    Di Pauli, Franziska
    Deisenhammer, Florian
    Lutterotti, Andreas
    Berger, Thomas
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2018, 23 : 74 - 77
  • [34] Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple Sclerosis
    Bischof, Antje
    Papinutto, Nico
    Keshavan, Anisha
    Rajesh, Anand
    Kirkish, Gina
    Zhang, Xinheng
    Mallott, Jacob M.
    Asteggiano, Carlo
    Sacco, Simone
    Gundel, Tristan J.
    Zhao, Chao
    Stern, William A.
    Caverzasi, Eduardo
    Zhou, Yifan
    Gomez, Refujia
    Ragan, Nicholas R.
    Santaniello, Adam
    Zhu, Alyssa H.
    Juwono, Jeremy
    Bevan, Carolyn J.
    Bove, Riley M.
    Crabtree, Elizabeth
    Gelfand, Jeffrey M.
    Goodin, Douglas S.
    Graves, Jennifer S.
    Green, Ari J.
    Oksenberg, Jorge R.
    Waubant, Emmanuelle
    Wilson, Michael R.
    Zamvil, Scott S.
    Cree, Bruce A. C.
    Hauser, Stephen L.
    Henry, Roland G.
    ANNALS OF NEUROLOGY, 2022, 91 (02) : 268 - 281
  • [35] Monitoring interferon treatment response with magnetic resonance spectroscopy in relapsing remitting multiple sclerosis
    Yetkin, Mehmet Fatih
    Mirza, Meral
    Donmez, Halil
    MEDICINE, 2016, 95 (36)
  • [36] CSF inflammatory markers: prediction of treatment response in early relapsing remitting multiple sclerosis?
    Marastoni, D.
    Pisani, A. I.
    Schiavi, G.
    Mazziotti, V.
    Castellaro, M.
    Crescenzo, F.
    Colombi, A.
    Pezzini, F.
    Pizzini, F. B.
    Calabrese, M.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 668 - 669
  • [37] Cytokines as Biomarkers of Treatment Response to IFN beta in Relapsing-Remitting Multiple Sclerosis
    Dimisianos, Nikolaos
    Rodi, Maria
    Kalavrizioti, Dimitra
    Georgiou, Vasileios
    Papathanasopoulos, Panagiotis
    Mouzaki, Athanasia
    MULTIPLE SCLEROSIS INTERNATIONAL, 2014, 2014
  • [38] Retinal layer thinning rate as a biomarker predicting treatment response in relapsing multiple sclerosis
    Bsteh, G.
    Hegen, H.
    Berek, K.
    Altmann, P.
    Wurth, S.
    Auer, M.
    Zinganell, A.
    Di Pauli, F.
    Rommer, P.
    Leutmezer, F.
    Deisenhammer, F.
    Berger, T.
    MULTIPLE SCLEROSIS JOURNAL, 2020, 26 (3_SUPPL) : 189 - 189
  • [39] Model (PHREND) for personalized prediction of treatment response in relapsing remitting multiple sclerosis (RRMS)
    Braune, S.
    van Hoevell, P.
    Stuehler, E.
    Drewek, A.
    Grimm, S.
    Ziemssen, T.
    Bergmann, A.
    MULTIPLE SCLEROSIS JOURNAL, 2017, 23 : 478 - 479
  • [40] Retinal layer thinning rate as a biomarker predicting treatment response in relapsing multiple sclerosis
    Bsteh, Gabriel
    Hegen, Harald
    Berek, Klaus
    Altmann, Patrick
    Zinganell, Anne
    Wurth, Sebastian
    Auer, Michael
    Di Pauli, Franziska
    Teuchner, Barbara
    Pemp, Berthold
    Deisenhammer, Florian
    Berger, Thomas
    NEUROLOGY, 2020, 94 (15)